Oren Livnat

H.C. Wainwright & Co.

Recent Articles

Strong Early Launch Metrics for Biotech's Skin Disease Drug 11/20/2023

Oren Livnat of H.C. Wainwright & Co. sees over 240% upside potential for Verrica Pharmaceuticals based on the early commercial success of its recently launched skin disease treatment.